Hologic Showcases Comprehensive Breast and Skeletal Health Solutions at RSNA 2022

By MedImaging International staff writers
Posted on 29 Nov 2022

Image: The 3Dimensions mammography system is the first DBT system to receive EUREF Type Test Certification (Photo courtesy of Hologic)

Hologic, Inc. (Marlborough, MA, USA) is exhibiting its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions are Hologic’s Affirm Contrast Biopsy software, which is on display for the first time since becoming commercially available in the U.S.

Affirm Contrast Biopsy software allows clinicians to target and acquire tissue samples in lesions identified with I-View Contrast-Enhanced Mammography software. The contrast solution provides healthcare facilities with a viable and attractive alternative to breast MRI, which historically has been used to find and biopsy more elusive lesions, such as those that cannot be seen via mammography or ultrasound. While breast MRI can be time-consuming and costly, contrast technology gives radiologists another option in the mammography suite that addresses these shortcomings. In a recent clinical study, 98% of patients had an overall positive opinion of their procedure experience with Affirm Contrast Biopsy software.

RSNA attendees can experience Hologic’s portfolio at Booth 1911 in South Hall Level 3 at McCormick Place in Chicago. In addition to the AffirmContrast Biopsy software, Hologic is featuring its Dimensions mammography portfolio and Supersonic MACH ultrasound systems. Hologic is also hosting a series of CME- and non-CME-accredited medical education symposiums and learning opportunities, accessible to attendees on-site and from remote locations.

“As the global leader in breast imaging, we are committed to addressing the unmet needs of physicians and their patients across the continuum of breast care and we’re eager to engage with industry leaders at this year’s RSNA meeting to share our vision for the future of breast health,” said Erik Anderson, President of Hologic’s Breast and Skeletal Health Solutions Division. “We are equally excited to showcase our new Affirm Contrast Biopsy technology, which is a great example of our commitment to physicians and patients in action.”

Related Links:
Hologic, Inc.